Additional file 1 of The in-vivo dynamics of Plasmodium falciparum HRP2: implications for the use of rapid diagnostic tests in malaria elimination
Creators: name: Marquart, Louise
name: Webb, Lachlan
name: O’Rourke, Peter
name: Gatton, Michelle L.
name: Hsiang, Michelle S.
name: Kalnoky, Michael
name: Jang, Ihn Kyung
name: Ntuku, Henry
name: Mumbengegwi, Davis R.
name: Domingo, Gonzalo J.
name: McCarthy, James S.
name: Britton, Sumudu
Publisher: name: figshare
Year: 2022
Subjects: subject: Medicine
subject: Microbiology
subject: FOS: Biological sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Information Systems not elsewhere classified
subject: Mathematical Sciences not elsewhere classified
subject: Cancer
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Computational Biology

description: Additional file 1: Material S1. Anti-malarial treatment details for IBSM individuals. Table S1. Antimalarial treatment given for the 15 IBSM individuals from four different studies, as identified with the clinical trial name and clinical trial ID. The antimalarial and dose given at day of treatment on Day 7 is detailed for each subject. Material S2. Methods to fit PfHRP2 model to the 6 individuals from the Namibia longitudinal cohort study. Table S2. Model performance of the Base model and red the Final model for the 15 IBSM individuals. Performance measures were the number (%) of PfHRP2 observations within the range of the predicted minimum and maximum PfHRP2 concentrations, the residual sum of squares (RSS) and the residual mean sum of square (RMSE). Table S3. Model performance of the updated model with PfHRP2 half-life estimate of 1.67 days applied to 6 individuals aged between 23 and 27 years from the study in Namibia in participants with Plasmodium falciparum mono-infection. Performance measures were the number (%) of PfHRP2 observations within the range of the predicted minimum and maximum PfHRP2 concentrations, the residual sum of squares (RSS), residual mean sum of square (RMSE), the predicted and observed days above 800 or 80 pg/mL. Figure S1. Fits of the Base Model and the Final Model for the 15 IBSM individuals. The observed parasitemia over the course of infection is represented by black solid line, observed PfHRP2 concentration is represented by circles (pre-treatment in solid circles and post-treatment in open circles), and the predicted minimum and maximum PfHRP2 concentration from the model is shown as blue and red dashed lines, respectively. Figure S2. Simulated parasitemia growth and clearance over the course of the infection for each of the 6 individuals from the Namibia longitudinal cohort study is represented by the black line. The observed parasitemia (parasites/mL) during the study are represented by the blue triangles and the replicating parasites used as input into the PfHRP2 model are represented by open circles. Figure S3. Fits of the final model with elimination half-life of 1.67 days to the 6 individuals from the Namibia longitudinal cohort study, with observed PfHRP2 concentration represented by closed circles, and minimum and maximum predicted PfHRP2 concentration represented by the blue and red dashed lines, respectively. The dashed grey horizontal line represents the threshold of 800 pg/mL and the solid grey horizontal line represents the threshold of 80 pg/mL which correspond to the positivity threshold of an RDT and usRDT respectively.